Antitumor effects of carnertinib in castration resistant prostate cancer models: A Comparative study with erlotinib

GL Gravina, F Marampon, M Piccolella, L Biordi… - The …, 2011 - Wiley Online Library
Abstract BACKGROUND AND PURPOSE Although preclinical results suggest that the
inhibition of erb‐B1 or erb‐B2 can be an useful tool to castration resistant prostate cancer …
被引用次数：11 相关文章

Antitumor effects of carnertinib in castration resistant prostate cancer models: a comparative study with erlotinib

GL Gravina, F Marampon, M Piccolella… - The …, 2011 - pubmed.ncbi.nlm.nih.gov
Background and purpose Although preclinical results suggest that the inhibition of erb-B1 or
erb-B2 can be an useful tool to castration resistant prostate cancer (CRPC), neither inhibitor …

Antitumor effects of carnertinib in castration resistant prostate cancer models: A Comparative study with erlotinib.

GL Gravina, F Marampon, P Margherita, B Leda… - THE …, 2011 - iris.uniroma1.it
BACKGROUND AND PURPOSE. Although preclinical results suggest that the inhibition of
erb-B1 or erb-B2 can be an useful tool to castration resistant prostate cancer (CRPC) …

Antitumor effects of carnertinib in castration resistant prostate cancer models: a comparative study with erlotinib

GL Gravina, F Marampon, M Piccolella, L Biordi… - THE …, 2011 - air.unimi.it
BACKGROUND AND PURPOSE. Although preclinical results suggest that the inhibition of
erb-B1 or erb-B2 can be an useful tool to castration resistant prostate cancer (CRPC) …

[引用][C] Antitumor Effects of Carnertinib in Castration Resistant Prostate Cancer Models: A Comparative Study With Erlotinib

GL GRAVINA, F MARAMPON, M PICCOLELLA… - The …, 2011 - pascal-francis.inist.fr
Antitumor Effects of Carnertinib in Castration Resistant Prostate Cancer Models: A
Comparative Study With Erlotinib CNRS Inist Pascal-Francis CNRS Pascal and Francis …

Antitumor effects of carnertinib in castration resistant prostate cancer models: A comparative study with erlotinib

GL Gravina, F Marampon, M Piccolella, L Biordi… - The Prostate, 2011 - infona.pl
BACKGROUND AND PURPOSE Although preclinical results suggest that the inhibition of
erb‐B1 or erb‐B2 can be an useful tool to castration resistant prostate cancer (CRPC) …

[引用][C] Antitumor effects of carnertinib in castration resistant prostate cancer models: A Comparative study with erlotinib.

G Gravina, F Marampon, M Piccolella, L Biordi… - THE …, 2011 - art.torvergata.it
Antitumor effects of carnertinib in castration resistant prostate cancer models: A Comparative
study with erlotinib. IRIS IRIS Home Sfoglia Macrotipologie & tipologie Autore Titolo Riviste Serie …
[PDF] academia.edu

[PDF][PDF] Antitumor Effects of Carnertinib in Castration Resistant Prostate Cancer Models: AComparative Study With Erlotinib

GL Gravina, F Marampon, M Piccolella, L Biordi… - The Prostate, 2011 - academia.edu
BACKGROUND AND PURPOSE. Although preclinical results suggest that the inhibition of
erb-B1 or erb-B2 can be an useful tool to castration resistant prostate cancer (CRPC) …

Antitumor effects of carnertinib in castration resistant prostate cancer models: A Comparative study with erlotinib

GL Gravina, F Marampon, M Piccolella, L Biordi… - Prostate, 2011 - hero.epa.gov
BACKGROUND AND PURPOSE: Although preclinical results suggest that the inhibition of
erb-B1 or erb-B2 can be an useful tool to castration resistant prostate cancer (CRPC) …

Antitumor effects of carnertinib in castration resistant prostate cancer models: a comparative study with erlotinib.

GL Gravina, F Marampon, M Piccolella, L Biordi… - The Prostate, 2011 - europepmc.org
Background and purpose Although preclinical results suggest that the inhibition of erb-B1 or
erb-B2 can be an useful tool to castration resistant prostate cancer (CRPC), neither inhibitor …